Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($3.07), $0.37 better than the analyst estimate of ($3.44). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $5.17 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
• RH (RH) Tops Q1 EPS by 12c